



Replacement Sheet
Sheet 1 of 17
Appl. No. 09/942,583; Filed: Aug 31, 2001
Dkt No. 1581.0840001/RWE/FRC; Group Unit: 1645
Inventors: ROBINSON et al.
Tel. No.: 202-371-2600
For: Neisserial Vaccine Compositions and Methods

FIG. 1

Challenge dose 10^8 CFU




FIG. 6




FIG.2A





FIG.2B






FIG.2C




FIG.3




FIG.4

FIG. 5A





FIG. 5B








Fig. 7




Key	Name	Parameter	Gate
—	N. cinerea NRL32165 pMIDG100	FL1-H	G1
■	N. cinerea NRL32165 pMIDG101	FL1-H	G1

FIG.8A




Key	Name	Parameter	Gate
—	N. flava NRL30008 pMIDG100	FL1-H	G1
■	N. flava NRL30008 pMIDG101	FL1-H	G1

FIG.8B




Key	Name	Parameter	Gate
—	N. sicca M98-252234 pMIDG100	FL1-H	G1
■	N. sicca M98-252234 pMIDG101	FL1-H	G1

FIG.8C



Key	Name	Parameter	Gate
—	N. subflava NRL30017 pMIDG100	FL1-H	G1
■	N. subflava NRL30017 pMIDG101	FL1-H	G1

FIG.8D



Key	Name	Parameter	Gate
—	N. flavescens 2830 pMIDG100	FL1-H	G1
■	N. flavescens 2830 pMIDG101	FL1-H	G1

FIG.8E




FIG.9A





FIG.9B

Fig. 10



*Nco*I - tgaccataaaaggaaccaaaaatagaaaaaagcacttgccacactgattgccctcgctctcccgccgcgcgcactggcggaagcgcatccttta
RBS Start codon
cgtccaagccgatgccgcacacgcaaaaagctcaagctctttaggttctgcaaaaggcttcagcccgccatctccgcaggctaccgcatcaacgacctccgcttcgccgt
cgattacacgcgctacaaaaataaaagcccatccaccgatttcaaactttacagcatcggcgcgtccgccattacgacttcgacacccaatcgccccgtcaaaccgatatct
cggcgcgcgcttgagcctcaaccgcctccgtcgacttggcgcgcagcgacagcttcagcaaacctccatcggctcgcgcgtattgacggcgttaagctatgcggtta
ccccgaatgtcgattggatgccggtaccgctacaactacatcggcaaagtcaacatgtcaaaaagctcggtccgcgaaactgtccgtcgcgcgtcgcgcgtcaaatctga
tatgcgccttattctgcaaacgcgcgagccttcggcggtttgtttct ~ *Ps*I
Stop codon Transcription terminator




FIG.12A




FIG.12C




FIG.12B




FIG.12D

Z8948 C2a:P1.5.2 (ET37)




FIG. 12E

High dose (2.3×10^6)




FIG. 12F

NZ 394/98 B4:P1.6 (Lineage 3)




FIG. 12G

High dose (7.5×10^7)




FIG. 12H




FIG. 12I




FIG. 12J




FIG. 13C




FIG. 13D




FIG. 13A





FIG. 13B

Fig. 14. *N. lactamica* OMVs with Freund's or alum adjuvant protect mice against serogroup B meningococcal challenge (isolate K454)

Challenge dose 4.35×10^6 CFU



Hours post challenge

**** $p = < 0.001$**

■ No vaccine **■ OMV ALOH**
□ OMV Freund's **■ LMW ALOH**